A. T. Chan
The Chinese University of Hong Kong
6 Papers
27 Citations
A. T. Chan is an academic researcher from The Chinese University of Hong Kong. The author has contributed to research in topics: Cancer & GemOx. The author has an hindex of 4, co-authored 6 publications.
Chat about Author
Papers
Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas
Alvaro Lassaletta,Michal Zapotocky,Matthew Mistry,Vijay Ramaswamy,Marion Honnorat,Rahul Krishnatry,Ana Guerreiro Stucklin,Nataliya Zhukova,Anthony Arnoldo,Scott Ryall,Catriona Ling,Tara McKeown,Jim Loukides,Ofelia Cruz,Carmen de Torres,Cheng-Ying Ho,Roger J. Packer,Ruth G. Tatevossian,Ibrahim Qaddoumi,Julie H. Harreld,James Dalton,Jean Mulcahy-Levy,Nicholas K. Foreman,Matthias A. Karajannis,Shiyang Wang,Matija Snuderl,Amulya A. Nageswara Rao,Caterina Giannini,Mark W. Kieran,Keith L. Ligon,Maria Luisa Garrè,Paolo Nozza,Samantha Mascelli,Alessandro Raso,Sabine Mueller,Theodore Nicolaides,Karen Silva,Romain Perbet,Alexandre Vasiljevic,Cecile Faure Conter,Didier Frappaz,Sarah Leary,Courtney A. Crane,A. T. Chan,Ho Keung Ng,Zhi Feng Shi,Ying Mao,Elizabeth Finch,David D. Eisenstat,Bev Wilson,Anne Sophie Carret,Peter Hauser,David Sumerauer,Lenka Krskova,Valerie Larouche,Adam J Fleming,Shayna Zelcer,Nada Jabado,James T. Rutka,Peter B. Dirks,Michael D. Taylor,Shiyi Chen,Ute Bartels,Annie Huang,David W. Ellison,Eric Bouffet,Cynthia Hawkins,Uri Tabori +67 more
TL;DR: BRAF V600E PLGG constitutes a distinct entity with poor prognosis when treated with current adjuvant therapy, and additional multivariable clinical and molecular stratification revealed that the extent of resection and CDKN2A deletion contributed independently to poor outcome in BRAF V 600E PL GG.
Final results of a phase III randomized study of concurrent weekly cisplatin-RT versus RT alone in locoregionally advanced nasopharyngeal carcinoma (NPC)
A. T. Chan,Roger K.C. Ngan,Peter M.L. Teo,Sing F. Leung,H. Y. Yiu,Winnie Yeo,Tony Mok,FY Cheung,Wing Hong Kwan,B. Zee +9 more
TL;DR: This randomized phase III study compared concurrent weekly cisplatin-RT with RT alone in patients with locoregionally advanced NPC, finding that 3 cycles of 3-weekly chemotherapy concurrent with RT followed by3 cycles of adjuvant chemotherapy has improved survival over RT alone.
9
A phase I/II study of belinostat (PXD101) in patients with unresectable hepatocellular carcinoma
Winnie Yeo,Robert Lim,Brigette B.Y. Ma,Pun Hui,Lisa Y.S. Chan,Frankie Kf Mo,Simon C.H. Yu,S. S. Ho,Jane Koh,A. T. Chan,Boon Cher Goh +10 more
TL;DR: This data indicates that Hepatocellular carcinoma is a highly aggressive tumor with 90% presenting with unresectable disease, resulting in a 60-year-old woman with a high likelihood of developing breast cancer.
8
Efficacy of neoadjuvant docetaxel and cisplatin followed by concurrent cisplatin-radiotherapy in locally advanced nasopharyngeal carcinoma (NPC): A randomized phase II study
Edwin P. Hui,Brigette B.Y. Ma,Sing F. Leung,Ann D. King,Frankie Kf Mo,M. K. Kam,K. H. Yu,Wing Hong Kwan,B. Zee,A. T. Chan +9 more
TL;DR: The safety and efficacy of neoadjuvant chemotherapy (neoadj) followed by CRT and cisplatin-RT were compared to improve survival and quality of life.
7
Biweekly gemcitabine and oxaliplatin (GEMOX) in first-line metastatic or recurrent nasopharyngeal carcinoma (NPC)--An early report
A. T. Chan,Brigette B.Y. Ma,Stewart Y. Tung,Edwin P. Hui,K. K. Yuen,Ann D. King,Sing F. Leung,Iris H.S. Chan,M. Chan,B. Zee +9 more
TL;DR: This multicenter phase II study evaluated the activity & safety of oxaliplatin (Ox), a 3rd generation platinum, in combination with gemcitabine (GEM) for the first time in the palliative setting for patients with undifferentiated/ poorly differentiated NPC.
2